World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
133
Citations
75396
World Ranking
371
National Ranking
244

Medicine

D-Index
132
Citations
73247
World Ranking
2297
National Ranking
1299

Overview

James E. Bradner is affiliated with Amgen in the United States and has contributed extensively to the fields of biochemistry, genetics, molecular biology, and medicine. Their research spans several subfields, including molecular biology, oncology, hematology, immunology, and neurology.

The primary focus of their work includes topics related to protein degradation and inhibitors, epigenetics and DNA methylation, CAR-T cell therapy research, ubiquitin and proteasome pathways, multiple myeloma research and treatments, peptidase inhibition and analysis, and genomics and chromatin dynamics.

James E. Bradner's recent publications showcase a range of studies primarily published between 2020 and 2021. Notable papers include:

  • "BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia," 2021, Journal of Clinical Investigation
  • "Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma," 2020, Journal of Clinical Investigation
  • "Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer," 2021, Science Advances
  • "Targeting oncoproteins with a positive selection assay for protein degraders," 2021, Science Advances
  • "An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity," 2020, Cell chemical biology

The scientist collaborates frequently with several coauthors, including Christopher J. Ott, Joshiawa Paulk, Jun Qi, Nathanael S. Gray, and Charles Y. Lin.

James E. Bradner's work is published predominantly in a few key venues. These venues include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Science Advances
  • Journal of Clinical Investigation
  • Cell chemical biology
  • JCI Insight

Best Publications

  • Selective inhibition of BET bromodomains.

    Panagis Filippakopoulos;Jun Qi;Sarah Picaud;Yao Shen

  • BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

    Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl

  • Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

    Jakob Lovén;Heather A. Hoke;Charles Y. Lin;Charles Y. Lin;Ashley Lau

  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Johannes Zuber;Junwei Shi;Junwei Shi;Eric Wang;Amy R. Rappaport;Amy R. Rappaport

  • HDAC2 negatively regulates memory formation and synaptic plasticity

    Ji Song Guan;Stephen J. Haggarty;Emanuela Giacometti;Jan Hermen Dannenberg;Jan Hermen Dannenberg

  • Transcriptional Amplification in Tumor Cells with Elevated c-Myc

    Charles Y. Lin;Jakob Lovén;Peter B. Rahl;Ronald M. Paranal

  • Phthalimide conjugation as a strategy for in vivo target protein degradation

    Georg E. Winter;Dennis L. Buckley;Joshiawa Paulk;Justin M. Roberts

  • The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

    Gang Lu;Richard E. Middleton;Huahang Sun;MarkVic Naniong

  • Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

    Jayne M. Stommel;Alec C. Kimmelman;Haoqiang Ying;Roustem Nabioullin

  • Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

    Purva Bali;Michael Pranpat;James Bradner;Maria Balasis

  • Transcriptional Addiction in Cancer

    James E. Bradner;Denes Hnisz;Richard A. Young

  • R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling

    Rui Su;Lei Dong;Chenying Li;Sigrid Nachtergaele

  • Direct inhibition of the NOTCH transcription factor complex

    Raymond E. Moellering;Raymond E. Moellering;Melanie Cornejo;Tina N. Davis;Cristina Del Bianco

  • YY1 Is a Structural Regulator of Enhancer-Promoter Loops

    Abraham S. Weintraub;Charles H. Li;Alicia V. Zamudio;Alla A. Sigova

  • Chemical phylogenetics of histone deacetylases

    James E Bradner;Nathan West;Nathan West;Melissa L Grachan;Edward F Greenberg;Edward F Greenberg

  • PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Christopher Michael Gale;Eugene Lifshits

  • The dTAG system for immediate and target-specific protein degradation

    Behnam Nabet;Justin M. Roberts;Dennis L. Buckley;Dennis L. Buckley;Joshiawa Paulk;Joshiawa Paulk

  • Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Bjoern Chapuy;Michael R. McKeown;Charles Y. Lin;Stefano Monti

  • Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

    Teru Hideshima;James E. Bradner;Jason Wong;Dharminder Chauhan

  • A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

    Stefan Gröschel;Stefan Gröschel;Mathijs A Sanders;Remco Hoogenboezem;Elzo de Wit

Frequent Co-Authors

Ralph Mazitschek
Ralph Mazitschek Harvard University
Andrew L. Kung
Andrew L. Kung Memorial Sloan Kettering Cancer Center
Nathanael S. Gray
Nathanael S. Gray Stanford University
Stuart L. Schreiber
Stuart L. Schreiber Harvard University
William C. Hahn
William C. Hahn Dana-Farber Cancer Institute
Scott A. Armstrong
Scott A. Armstrong Harvard University
Kwok-Kin Wong
Kwok-Kin Wong New York University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Jon C. Aster
Jon C. Aster Harvard Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Biology and Biochemistry, there are a variety of related online degrees and pathways to further specialize or diversify your expertise in healthcare and life sciences. Many flexible programs now cater to professionals seeking both convenience and affordability in their studies.

Nurses aiming to advance their careers can explore options like the cheapest post master's fnp program or transition to new roles through online rn to bsn programs. For those interested in nutrition and wellness, earning a nutritionist degree online can open pathways in health promotion, dietetics, and clinical practice.

Professionals seeking leadership roles may consider advancing their credentials with an online masters in healthcare management. Each program offers unique opportunities to enhance your career, often with fast-track or budget-friendly options to suit your individual needs.

Best Scientists Citing James E. Bradner

Trending Scientists

Recently Published Articles